Novel Insights of Oligometastases and Oligo-recurrence and Review of the Literature

Overview

Journal Pulm Med

Publisher Wiley

Specialty Pulmonary Medicine

Date 2012 Sep 12

PMID 22966429

Citations 62

Authors

Yuzuru Niibe

Joe Y Chang

Affiliations

Soon will be listed here.

Abstract

Oligometastases and oligo-recurrence are among the most important notions of metastatic and recurrent cancer. The concept of oligometastases is related to the notion that cancer patients with 1-5 metastatic or recurrent lesions that could be treated by local therapy achieve long-term survival or cure, while the concept of oligo-recurrence is related to the notion that cancer patients with 1-5 metastatic or recurrent lesions that could be treated by local therapy have controlled primary lesions. Achievement of long-term survival or cure in patients with oligometastases and oligo-recurrence is cancer and organ specific. These facts rely on the seed and soil theory and multiple steps of cancer progression. Oligo-recurrence is considered to have a better prognosis than oligometastases. In patients with oligometastases and oligo-recurrence, the oligometastases and oligo-recurrence are sometimes cured with only local therapy, which is an example of the abscopal effect, previously described in relation to cure of lesions outside of the field of radiation therapy without systemic therapy. Oligometastases and oligo-recurrence can now be cured by less invasive local treatment methods combined with systemic therapy. The mechanisms of oligometastases and oligo-recurrence, as well as novel insights into these important concepts, are presented in this paper.

Citing Articles

Clinical and genetic drivers of oligo-metastatic disease in colon cancer.

Ottaiano A, Santorsola M, Sirica R, Di Mauro A, Di Carlo A, Ianniello M Neoplasia. 2024; 60:101111.

PMID: 39709701 PMC: 11846493. DOI: 10.1016/j.neo.2024.101111.

Predictive Value of the Prostate-specific Antigen Doubling Time for the Effectiveness of Metastasis-directed Radiotherapy in Patients With Oligometastases After Radical Treatment for Non-metastatic Prostate Cancer.

Koguchi D, Tabata K, Hirano S, Shimura S, Satoh T, Ikeda M Cancer Diagn Progn. 2024; 4(5):638-645.

PMID: 39238621 PMC: 11372687. DOI: 10.21873/cdp.10375.

Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence.

Werner R, Steinmann N, Decaluwe H, Date H, De Ruysscher D, Opitz I Eur Respir Rev. 2024; 33(172).

PMID: 38811031 PMC: 11134198. DOI: 10.1183/16000617.0200-2023.

Re-irradiation spine stereotactic body radiotherapy following high-dose conventional radiotherapy for metastatic epidural spinal cord compression: a retrospective study.

Koide Y, Haimoto S, Shimizu H, Aoyama T, Kitagawa T, Shindo Y Jpn J Radiol. 2024; 42(6):662-672.

PMID: 38413551 PMC: 11139739. DOI: 10.1007/s11604-024-01539-x.

Oligometastases of Esophageal Squamous Cell Carcinoma: A Review.

Sato Y, Tanaka Y, Yokoi R, Tsuchiya H, Sengoku Y, Fukada M Cancers (Basel). 2024; 16(4).

PMID: 38398095 PMC: 10886923. DOI: 10.3390/cancers16040704.

References

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1):37-49. DOI: 10.1016/s0022-5223(97)70397-0. View

Limmer S, Unger L . Optimal management of pulmonary metastases from colorectal cancer. Expert Rev Anticancer Ther. 2011; 11(10):1567-75. DOI: 10.1586/era.11.123. View

Rusthoven K, Kavanagh B, Cardenes H, Stieber V, Burri S, Feigenberg S . Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27(10):1572-8. DOI: 10.1200/JCO.2008.19.6329. View

Postow M, Callahan M, Barker C, Yamada Y, Yuan J, Kitano S . Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366(10):925-31. PMC: 3345206. DOI: 10.1056/NEJMoa1112824. View

Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C . Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys. 2006; 66(5):1366-9. DOI: 10.1016/j.ijrobp.2006.07.1384. View

Adam R, Wicherts D, de Haas R, Ciacio O, Levi F, Paule B . Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol. 2009; 27(11):1829-35. DOI: 10.1200/JCO.2008.19.9273. View

Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Ii N . Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol. 2006; 103(2):435-8. DOI: 10.1016/j.ygyno.2006.03.034. View

Niibe Y, Hayakawa K . Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010; 40(2):107-11. PMC: 2813545. DOI: 10.1093/jjco/hyp167. View

Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K . Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulm Med. 2012; 2012:454107. PMC: 3472526. DOI: 10.1155/2012/454107. View

10.

Huang E, Huang Y, Chanchien C, Lin H, Wang C, Sun L . Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiat Oncol. 2012; 7:13. PMC: 3298789. DOI: 10.1186/1748-717X-7-13. View

11.

Onaitis M, Petersen R, Haney J, Saltz L, Park B, Flores R . Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg. 2009; 87(6):1684-8. DOI: 10.1016/j.athoracsur.2009.03.034. View

12.

Monteiro J, Fodde R . Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer. 2010; 46(7):1198-203. DOI: 10.1016/j.ejca.2010.02.030. View

13.

Langley R, Fidler I . The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011; 128(11):2527-35. PMC: 3075088. DOI: 10.1002/ijc.26031. View

14.

Okunieff P, Petersen A, Philip A, Milano M, Katz A, Boros L . Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006; 45(7):808-17. DOI: 10.1080/02841860600908954. View

15.

Inoue T, Katoh N, Onimaru R, Shirato H . Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence. Pulm Med. 2012; 2012:369820. PMC: 3399335. DOI: 10.1155/2012/369820. View

16.

Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D . Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996; 224(4):509-20; discussion 520-2. PMC: 1235414. DOI: 10.1097/00000658-199610000-00009. View

17.

Pawlik T, Scoggins C, Zorzi D, Abdalla E, Andres A, Eng C . Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005; 241(5):715-22, discussion 722-4. PMC: 1357126. DOI: 10.1097/01.sla.0000160703.75808.7d. View

18.

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

19.

van der Pool A, Mendez Romero A, Wunderink W, Heijmen B, Levendag P, Verhoef C . Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010; 97(3):377-82. DOI: 10.1002/bjs.6895. View

20.

Perego D, Faravelli A . Unexpected consequence of splenectomy in composite lymphoma. The abscopal effect. Haematologica. 2000; 85(2):211. View